Beijing Farber Xintian Pharmaceutical Technology Co., Ltd.

本研究的主要目的是： 评价锝[99mTc]-H7ND注射液在胃肠道恶性肿瘤患者和健康人中的安全性。 本研究的次要目的是： （1）检测锝[99mTc]-H7ND注射液在健康人体内的药代动力学。 （2）检测锝[99mTc]-H7ND注射液在健康人体内的代谢稳定性。 （3）检测锝[99mTc]-H7ND注射液在胃肠道恶性肿瘤患者和健康人体内的生物分布及估算内照射辐射吸收剂量。

The primary objective of this study is: to evaluate the safety of technetium [99mTc]-H7ND injection in patients with gastrointestinal malignancies and in healthy subjects. The secondary objectives of this study are: (1) to examine the pharmacokinetics of technetium [99mTc]-H7ND Injection in healthy subjects. (2) Detect the metabolic stability of technetium [99mTc]-H7ND injection in healthy humans. (3) Detect the biodistribution and estimate the absorbed dose of radiation from internal irradiation of technetium [99mTc]-H7ND injection in patients with malignant tumors of the gastrointestinal tract and in healthy humans.

Objective: To evaluate the efficacy and safety of Ningmitai Capsules and Silodosin Capsules in the treatment of Benign Prostatic Hyperplasia (BPH) with Lower Urinary Tract Symptoms (LUTS) compared with Tamsulosin Hydrochloride Sustained Release Capsules.
Study design: A multicenter, prospective, randomized, double-blind, positive controlled clinical study.
Interventions:
Group A: Oral Tamsulosin Hydrochloride Capsules and Ningmitai Capsules placebo for 12 weeks.
Group B: Oral l Silodosin Capsules and Ningmitai Capsules placebo for 12 weeks. Group C: Oral l Silodosin Capsules and Ningmitai Capsules for 12 weeks.